---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-013984"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2025-03-20T23:59:59+00:00"
generated_at: "2026-05-24T10:09:37.969049+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Avalo reports 2024 net loss of $35.1M; cash of $134.5M funds into at least 2027

## Summary
- Cash and equivalents $134.5M at Dec 31, 2024 vs $7.4M in 2023; runway into at least 2027.
- Net loss $35.1M in 2024 ($7.94 basic EPS) vs $31.5M loss in 2023; diluted EPS -$20.91.
- R&D expense $24.4M, up $10.7M, driven by Phase 2 LOTUS trial of AVTX-009 in hidradenitis suppurativa.
- Topline data from Phase 2 LOTUS trial expected in 2026; second indication for AVTX-009 planned.
- Appointed Jennifer Riley as Chief Strategy Officer effective January 1, 2025.

## SEC filing metadata
- accession: 0001628280-25-013984
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2025-03-20T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000162828025013984/0001628280-25-013984-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000162828025013984/avtx-20250320.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-013984
- JSON: https://secwatch.observer/filing/0001628280-25-013984.json
- Plain text: https://secwatch.observer/filing/0001628280-25-013984.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.